Topics

Agilent Expands Cell Analysis Business with Planned $1.2B BioTek Acquisition

08:00 EDT 12 Jul 2019 | Genetic Engineering News

The acquisition of BioTek will solidify Agilent’s position in cell analysis, and particularly in the spaces of immuno-oncology and immunotherapy overall. Once the deal is closed, Agilent’s total cell analysis business will have grown to more than $250 million in annual revenues.

The post Agilent Expands Cell Analysis Business with Planned $1.2B BioTek Acquisition appeared first on GEN - Genetic Engineering and Biotechnology News.

Original Article: Agilent Expands Cell Analysis Business with Planned $1.2B BioTek Acquisition

NEXT ARTICLE

More From BioPortfolio on "Agilent Expands Cell Analysis Business with Planned $1.2B BioTek Acquisition"

Quick Search

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...